Updated for 2026
FNP pulmonology: COPD, asthma, and respiratory disease management
Respiratory disease is among the most common reason for primary care visits. FNP certification exams test spirometry interpretation, GOLD COPD staging and stepwise treatment, GINA asthma stepwise therapy, pneumonia diagnosis and treatment selection (CAP vs. HAP), and pulmonary preventive care.
Educational purpose: This content is for exam preparation and professional development only. It is not intended for clinical decision-making. Always follow current guidelines, institutional policies, and scope of practice.
COPD — GOLD 2024 guidelines for FNP practice
COPD diagnosis requires post-bronchodilator spirometry: FEV1/FVC <0.70. GOLD grades severity by FEV1% predicted. Clinical management uses the ABCD assessment combining spirometry grade, symptom burden (mMRC dyspnoea scale or CAT score), and exacerbation history.
GOLD 2024 initial pharmacotherapy:
- Group A (low symptoms, low exacerbation risk): Long-acting bronchodilator (LABA or LAMA) PRN or scheduled
- Group B (high symptoms, low exacerbation risk): LABA + LAMA combination (evidence of superiority over monotherapy)
- Group E (high exacerbation risk, any symptom level): LABA + LAMA; if eosinophils ≥300 cells/μL or frequent exacerbations → LABA + LAMA + ICS (triple therapy)
Key prescribing principles: Short-acting beta-agonist (SABA — albuterol) for rescue. Long-acting muscarinic antagonist (LAMA — tiotropium, umeclidinium, glycopyrrolate) reduces exacerbations. Inhaled corticosteroids (ICS) only if eosinophilia or frequent exacerbations — avoid monotherapy ICS in COPD (increased pneumonia risk). Roflumilast (PDE4 inhibitor) add-on for severe COPD with chronic bronchitis and frequent exacerbations. Pulmonary rehabilitation for mMRC ≥2 or CAT ≥10.
COPD exacerbation management: SABAs and SAMAs (ipratropium), systemic corticosteroids (prednisone 40 mg × 5 days — equivalent to 14 days in REDUCE trial), antibiotics (amoxicillin-clavulanate, azithromycin, or doxycycline for purulent sputum or severe exacerbation), and supplemental oxygen (titrate to 88–92% in known CO2 retainers).
Asthma — GINA 2024 stepwise approach
GINA 2024 has fundamentally changed asthma management: scheduled daily SABA use is no longer recommended. All patients with asthma should have either ICS-containing reliever therapy or ICS-LABA.
GINA 2024 stepwise treatment:
- Steps 1–2 (mild): As-needed low-dose ICS-formoterol (preferred over SABA alone — reduces exacerbation risk)
- Step 3 (moderate): Low-dose ICS-LABA maintenance + as-needed ICS-formoterol
- Step 4: Medium-dose ICS-LABA maintenance + as-needed ICS-formoterol
- Step 5: High-dose ICS-LABA + add-on LAMA; specialist referral; consider biologics (dupilumab, mepolizumab, omalizumab)
Biologic therapy eligibility: Eosinophilic asthma (eosinophils ≥300 cells/μL): IL-5 antagonists (mepolizumab, benralizumab) or dupilumab. Allergic asthma with elevated IgE: omalizumab. These are add-on treatments for uncontrolled severe asthma despite steps 4–5 and should be initiated in specialist consultation.
FNP asthma monitoring: Asthma control assessment at every visit: symptom frequency, nocturnal awakening, rescue inhaler use, activity limitation. ACT (Asthma Control Test) score ≥20 = well-controlled. Peak flow: compare to personal best, not predicted. Written asthma action plan for all patients.
Frequently asked questions
- What is the most significant change in the GINA 2024 asthma guidelines for FNP practice?
- The most significant paradigm shift: GINA 2024 recommends against scheduled daily SABA (albuterol) use even for mild asthma. Instead, as-needed low-dose ICS-formoterol (e.g., budesonide-formoterol) is preferred for Step 1 and Step 2 patients. This is called SMART therapy (Single Maintenance And Reliever Therapy) at Steps 3-5. The evidence shows that as-needed ICS-formoterol reduces severe exacerbations by ~60–70% compared to as-needed SABA alone, even in patients who only occasionally need a reliever. FNP certification exams now test this updated first-line recommendation — selecting 'albuterol PRN' as the only treatment for mild asthma would be a suboptimal answer per current GINA guidelines.
Clinically reviewed by NurseNest Clinical Review Team · Last updated 2026-06-10 · For educational purposes only · Review policy